ideology-health
  • Our Solutions
  • About Us
    • ideology-health
    Privacy Policy
    Terms of Service

    IDEOlogy Health Ranks No. 772 on the 2025 Inc. 5000 Fastest-Growing Private Companies in America

    © 2025 IDEOlogy Health. All product names, logos, brands, trademarks and registered trademarks are property of their respective owners and their use(s) do not necessarily imply endorsement.

    S

    Dr Sara Tolaney, MD

    Medical professional dedicated to sharing knowledge and insights through educational videos.

    Dr. Sara Tolaney discusses the potential impact of 1L sacituzumab govitecan on clinical practice in PDL1+ mTNBC (Video 3/3)

    Dr. Sara Tolaney discusses the potential impact of 1L sacituzumab govitecan on clinical practice in PDL1+ mTNBC (Video 3/3)

    ASCENT04- Impact on clinical practice

    Sara Tolaney, MD
    ASCO Updates
    Breast Cancer
    +1 more
    Dr. Sara Tolaney reviews the safety profile and management strategies for sacituzumab govitecan in 1L PDL1+ mTNBC (Video 2/3)

    Dr. Sara Tolaney reviews the safety profile and management strategies for sacituzumab govitecan in 1L PDL1+ mTNBC (Video 2/3)

    ASCENT04-Safety & management

    Sara Tolaney, MD
    ASCO Updates
    Breast Cancer
    +1 more
    Dr. Sara Tolaney highlights the key efficacy outcomes of sacituzumab govitecan in 1L PDL1+ mTNBC (Video 1/3)

    Dr. Sara Tolaney highlights the key efficacy outcomes of sacituzumab govitecan in 1L PDL1+ mTNBC (Video 1/3)

    ASCENT04- Key efficacy outcomes

    Sara Tolaney, MD
    ASCO Updates
    Breast Cancer
    +1 more